Simplified Exercise-based Risk Assessment in Lung Cancer

Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Surgical resection offers a potential cure in selected patients; however, the risk of serious postoperative cardiopulmonary complications is substantial. Accurate pre-treatment risk stratification is therefore critical to guide treatment decisions, optimize perioperative care, and improve outcomes. Current clinical practice includes cardiopulmonary exercise testing (CPET) to assess physiological reserve, particularly peak oxygen uptake (VO₂peak) and ventilatory efficiency (VE/VCO₂ slope). While effective, CPET is resource-intensive, requiring specialized equipment and trained personnel, limiting its availability in many healthcare settings.

This study evaluates a simplified, low-resource method for assessing ventilatory efficiency using end-tidal carbon dioxide (PetCO₂) measured during a short, low-intensity cycling test. Prior research has demonstrated that PetCO₂ reflects ventilatory efficiency and has predictive value comparable to CPET-derived measures for postoperative complications. Notably, PetCO₂ measured during low-intensity exercise appears to provide the strongest prognostic signal. Because PetCO₂ can be obtained using a portable device with a nasal cannula, this approach has the potential to enable accessible, scalable physiological risk assessment.

The primary objective is to determine whether PetCO₂ measured during a standardized low-intensity cycle ergometer test can identify patients at low versus high risk of major complications or death within 90 days following lung cancer surgery (lobectomy). Secondary objectives include: (1) comparison of predictive accuracy with established CPET-based risk stratification; (2) evaluation of PetCO₂ as a predictor of severe adverse events during systemic cancer therapy (chemotherapy and/or immunotherapy); and (3) assessment of its prognostic value for two-year overall survival independent of treatment modality.

This is a prospective, multicenter cohort study conducted across multiple hospitals in Sweden, including regional and university centers. Patients referred for evaluation of suspected lung cancer are eligible for inclusion. The study is observational; all participants undergo standard diagnostic work-up and treatment according to routine clinical practice. The investigational test does not influence clinical decision-making, as results are not disclosed to treating clinicians.

Participants who provide informed consent perform a standardized, submaximal cycle ergometer test at a fixed low workload (20 W). PetCO₂ is measured continuously using a portable capnography device with nasal cannula before exercise, after 2 minutes of seated rest, and during 5 minutes of cycling. The test is brief (approximately 5 minutes), requires no change of clothing, and can be performed by trained healthcare personnel without specialized expertise.

Clinical and physiological data, including demographics, smoking status, lung function, and PetCO₂ measurements, are recorded in a centralized electronic data capture system (REDCap). Data are entered locally at each site using standardized case report forms. For participants undergoing CPET as part of routine care, CPET data are collected separately and linked for comparative analyses. A retrospective CPET dataset (2008-2023) will be used for validation of identified PetCO₂ thresholds.

Outcome data are obtained through structured medical record review performed by trained research staff blinded to baseline PetCO₂ values. The primary endpoint is a composite of major cardiopulmonary complications within 90 days of surgery, including events such as myocardial infarction, heart failure, arrhythmia, stroke, pulmonary embolism, pneumonia, respiratory failure, acute respiratory distress syndrome, or death. Secondary endpoints include severe adverse events (grade ≥3 according to CTCAE v5) during systemic therapy and all-cause mortality within two years, the latter assessed through linkage with national mortality registries.

The planned sample size is based on the primary endpoint and aims to include approximately 105 patients undergoing lobectomy, corresponding to an estimated total cohort of approximately 1,050 participants undergoing the index test. This calculation assumes an expected complication rate of approximately 14-17%, an area under the curve (AUC) of 0.70, 80% power, and a one-sided significance level of 0.05. Recruitment is expected to occur over approximately 18 months across participating sites.

Quality assurance procedures include the use of standardized operating procedures (SOPs) for test performance, data collection, and data entry across all sites. Training materials are provided to ensure consistency in test administration. Data validation is performed within the REDCap system using predefined range checks and consistency rules. Regular monitoring of data completeness and quality is conducted centrally. Source data verification is performed through comparison with medical records during outcome adjudication. Data are pseudonymized prior to analysis to ensure patient confidentiality.

A structured data dictionary defines all variables, including measurement methods, coding schemes, and clinically relevant ranges. Standardized definitions are used for clinical endpoints (e.g., CTCAE for adverse events), ensuring harmonization across sites. Procedures for handling missing or inconsistent data include predefined rules for exclusion, imputation, or sensitivity analyses, depending on the nature and extent of missingness.

The statistical analysis plan includes evaluation of predictive performance using receiver operating characteristic (ROC) analysis, estimation of optimal PetCO₂ thresholds, and comparison with CPET-derived metrics. Multivariable regression models will be used to adjust for potential confounders. Survival analyses will be conducted using time-to-event methods. Exploratory analyses will assess subgroup effects and treatment-specific outcomes.

The study poses minimal risk to participants, as the intervention consists of a brief, low-intensity exercise test comparable to activities of daily living. The primary risks relate to handling of sensitive personal data, which are mitigated through secure data management and pseudonymization. Ethical approval has been attained, and participation is voluntary with informed consent.

If validated, this simplified test could be rapidly implemented in routine care, improving access to physiological risk assessment, reducing reliance on resource-intensive testing, and supporting more efficient and individualized treatment decision-making in lung cancer care.

Inclusion criteria

• Lung Cancer Diagnosis
• Age of at least 18 years

Exclusion criteria

• Not able to perform cycle ergometer exercise
• Not able to understand spoken or written Swedish